Karyopharm Therapeutics Enhances Workforce with Restricted Stock Units for New Hires

Karyopharm Therapeutics Strengthens Talent Pool with New Stock Incentives

Karyopharm Therapeutics Inc. solidifies its commitment to innovative cancer therapies by announcing the grant of 1,450 restricted stock units (RSUs) to two newly-hired employees. This award, granted on February 28, 2026, as part of the 2022 Inducement Stock Incentive Plan, is designed to attract and retain key talent in a competitive pharmaceutical landscape. The RSUs will vest over three years at a rate of 33.33% annually, contingent upon the ongoing service of the employees with the company. This move underscores Karyopharm’s strategic focus on bolstering its workforce as it advances its pioneering research and product development.

As a commercial-stage pharmaceutical company, Karyopharm is at the forefront of addressing critical unmet medical needs in oncology. With its flagship product, XPOVIO® (selinexor), the company has established itself as a leader in targeting nuclear export dysregulation, a significant factor in cancer progression. XPOVIO is the first oral exportin 1 (XPO1) inhibitor approved in the United States for three oncology indications, with further regulatory clearance obtained across 50 territories globally, including the European Union and China, where it is marketed as NEXPOVIO®. This broad approval reflects Karyopharm's dedication to expanding access to its innovative therapies for cancer patients worldwide.

The company’s vision extends beyond its current product offerings, maintaining a robust pipeline aimed at several serious malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). Through its ongoing R&D endeavors, Karyopharm remains committed to revolutionizing cancer treatment and enhancing patient outcomes. The development of new therapies not only positions the company as a key player in oncology but also reinforces its mission to make a meaningful impact on cancer care. Karyopharm invites interested parties to follow their journey on their official website and social media platforms.

In addition to its hiring initiative, Karyopharm Therapeutics' focus on innovation speaks volumes about its long-term strategies in the pharmaceutical sector. The company plays a crucial role in addressing the significant challenges posed by cancer, ensuring that its advancements resonate with the needs of patients and healthcare providers alike. As Karyopharm continues to grow, it remains steadfast in its purpose to make strides in oncology care and treatment accessibility.